Current therapies for lupus nephritis in an ethnically heterogeneous cohort

Journal of Rheumatology

Volumn 36, Issue 2, 2009, Pages 298-305

  Rivera, Tania L ^a   Belmont, H Michael ^a   Malani, Seema ^b   Latorre, Melissa ^c   Benton, Lauri ^d   Weisstuch, Joseph ^a   Barisoni, Laura ^a   Tseng, Chung E ^a   Izmirly, Peter M ^a   Buyon, Jill P ^a   Askanase, Anca D ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK DOWNTOWN HOSPITAL   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cyclophosphamide; Hispanics; Lupus nephritis; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; DNA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SERUM ALBUMIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASIAN; CAUCASIAN; CHILD; CLINICAL EVALUATION; COMPLEMENT DISORDER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HEMODIALYSIS; HISPANIC; HUMAN; INCIDENCE; INFECTION; KIDNEY BIOPSY; KIDNEY EXAMINATION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEDIMENTATION RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; ETHNOLOGY; MIDDLE AGED; PRESCHOOL CHILD; RACE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; CREATININE; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SERUM ALBUMIN; YOUNG ADULT;

EID: 64849111984     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080335     Document Type: Article

References (18)

1. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619 (Pubitemid 16132725)
2. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-950
3. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-980 (Pubitemid 38269274)
4. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-1162
5. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-1084 (Pubitemid 41710318)
6. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-2228 (Pubitemid 41697285)
7. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007;22:1933-1942 (Pubitemid 47244763)
8. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action [review]. Immunopharmacology 2000;47:85-118. (Pubitemid 30394534)
9. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis [review]. Arthritis Res Ther 2006;8:R182. (Pubitemid 46306295)
10. Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in LN. [Internet. Accessed October 10, 2008.] Available from: http://www.aspreva.com/completenews.php?id=136
11. Fernandez M, Calvo-Alén J, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum 2005;52:1655-1664
12. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-530 (Pubitemid 38130646)
13. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619 (Pubitemid 16132725)
14. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Transplantation 1998;65:242-248
15. Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69:1846-1851 (Pubitemid 43739214)
16. Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-557
17. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-3940 (Pubitemid 39643941)
18. Schweitzer EJ, Yoon S, Fink J, et al. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Kidney Int 2006;69:1846-1851